These findings are consistent with our observation that CCR8 plays a critical role in Treg-mediated immune regulation, highlighting the therapeutic potential of targeting the CCL1–CCR8 axis to modulate Treg function and improve cancer immunotherapy outcomes. This evidence concerns the gene CCL1 and cancer.